J Asthma Allergy:中国南方过敏性鼻炎和哮喘患者的花生过敏以及与花粉过敏的交叉反应分析

2021-11-24 AlexYang MedSci原创

调查了中国南方人群过敏性鼻炎和/或哮喘患者的花生致敏性和与花粉过敏原的交叉反应情况。

近年来,过敏性疾病的发病率一直在增加,给社会带来了巨大的经济负担。在西方和东方国家,食物过敏和呼吸道过敏性疾病的患病率均急剧上升。许多植物过敏原,如泛过敏原,可与植物来源的食物和花粉过敏原中的同源蛋白发生交叉反应,引起花粉食物过敏综合征,这是一种由免疫球蛋白E(IgE)介导的常见过敏性疾病。

花生是西方国家最常报道的引起严重过敏的过敏原之一。但在中国,由花生引起的严重过敏的报道却很少

近期,来自广州医科大学的研究人员在《J Asthma Allergy》杂志上发表文章,调查了中国南方人群过敏性鼻炎和/或哮喘患者的花生致敏性和与花粉过敏原的交叉反应情况

研究人员用ImmunoCAP系统检测了58名过敏患者对Ara h 1、Ara h 8、Juglans花粉、Platanus花粉、桦树花粉、Bet v 1、Bet v 4和交叉反应的碳水化合物决定因子(CCD)的总IgE(tIgE)和特异性IgE(sIgE)抗体。其中33人花生IgE阳性,25人阴性,并进一步分析了花生过敏原和花粉过敏原之间的关系。

结果发现,9.1%(3/33)的花生过敏患者对Ara h 8过敏,而21.2%(7/33)的患者对Ara h 1过敏。花生过敏组对CCD(69.7% vs 4.0%)、Juglans花粉(87.9% vs 12.0%)、Platanus花粉(90.9% vs 16.0%)和桦树花粉(60.6% vs 4.0%)的sIgE抗体阳性率明显高于花生耐受组(所有P<0.05)。Spearman相关显示,花生的IgE与CCD(rs=0.859)、Juglans花粉(rs=0.772)、桔梗花粉(rs=0.838)和桦树花粉(rs=0.816)的sIgE显著相关。

花生、法国梧桐、桦树和胡桃过敏原过敏的韦恩图

综上所述,在中国南方,大多数对花生过敏的患者也对多种花粉过敏原过敏。花生过敏与法国梧桐、胡桃和桦树花粉过敏高度相关,表明花生和花粉过敏原之间可能存在交叉反应。因此,临床医生在花生过敏诊断和治疗中应注意区分诊断

 

原始出处:

Wenting Luo, Shuwen Yang, Huimin Huang et al. Analysis of Peanut Allergen Components Sensitization and Cross Reaction with Pollen Allergen in Chinese Southerners with Allergic Rhinitis and/or Asthma. J Asthma Allergy. Oct 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
    2022-05-11 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
    2021-11-25 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1712972, encodeId=fbfc1e1297263, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 10 07:11:19 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977183, encodeId=25f119e71833a, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed May 11 20:11:19 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047455, encodeId=7fb1204e45512, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Feb 16 13:11:19 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329577, encodeId=43d713295e7fb, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396453, encodeId=7c171396453d0, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507098, encodeId=2b59150e09840, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Thu Nov 25 11:11:19 CST 2021, time=2021-11-25, status=1, ipAttribution=)]

相关资讯

Allergy:早发特应性皮炎的恶化与儿童气源过敏原致敏和过敏性鼻炎的发生有关么?

调查了早发的重度特应性皮炎(AD)与气源性过敏原致敏和过敏性鼻炎的关系。

Allergol Immunopathol (Madr):过敏性鼻炎严重度与中性粒细胞/淋巴细胞、嗜酸性粒细胞/中性粒细胞和嗜酸性粒细胞/淋巴细胞比率的关系

调查了中性粒细胞与淋巴细胞比率(NLR)、嗜酸粒细胞与中性粒细胞比率(ENR)和嗜酸粒细胞与淋巴细胞比率(ELR)这三个炎症参数是否能够区分间歇过敏性鼻炎和持续过敏性鼻炎。

Eur Arch Otorhinolaryngol:透明质酸钠能否减轻过敏性鼻炎患者的鼻症状?

评估了在鼻腔皮质激素(NC)治疗中加入透明质酸(HA)或正常盐水(NSS)作为附加疗法,与单独的NC治疗相比,在改善间歇性AR儿童的生活质量和减少鼻部症状评分方面的临床效果。

Eur Arch Otorhinolaryngol:鼻腔细胞学方法诊断非过敏性鼻炎的表现如何?

鼻部病理可以通过症状学来表征,但难以区分过敏性鼻炎(AR)、非过敏性鼻炎(NAR)和慢性鼻窦炎(CRS)。鼻腔细胞学(NC)能够帮助临床医生区分鼻炎的各种亚型,其重要性日益增加。

Clin Respir J:AR与NAR患者的血清瘦素差异及血清瘦素的诊断价值

比较了过敏性鼻炎(AR)和非过敏性鼻炎(NAR)患者的血清瘦素水平,并评估了瘦素的诊断价值情况。

J Asthma Allergy:SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT?

在SAR患者中,16周的SCIT+dupilumab能够改善SCIT的耐受性。